SESSION XIII: CELLULAR THERAPY 

Session Chairs: Issa Khouri and Adetola Kassim

Gene Therapy Should Be the Cell Therapy of Choice for Sickle Cell Disease | Jaap-Jan Boelens, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Haploidentical Transplant Should Be the Cell Therapy Choice for Sickle Cell Disease | Adetola Kassim, MD, MS | Vanderbilt University Medical Center, Nashville, Tennessee, USA

Debate: CD19 CAR T Therapy Should Be the Preferred Therapy for Richter's Transformation | Nirav N Shah, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Debate: ALLO HCT Should Be the Preferred Therapy for Richter's Transformation | Issa F Khouri, MD | MD Anderson Cancer Center, Houston, Texas, USA